Učitavanje...
Checkpoint immunotherapy in head and neck cancers
Checkpoint inhibitors have recently gained FDA approval for the treatment of cisplatin-resistant recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) by outperforming standard of care chemotherapy and inducing durable responses in a subset of patients. These monoclonal antibodies u...
Spremljeno u:
| Izdano u: | Cancer Metastasis Rev |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7694874/ https://ncbi.nlm.nih.gov/pubmed/28836124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10555-017-9694-9 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|